Novartis AG to Acquire Regulus Therapeutics Inc. in a Landmark $1.7 Billion Deal

In a significant move that could reshape the biopharmaceutical landscape, Novartis AG has announced its agreement to acquire Regulus Therapeutics Inc. The deal, valued at up to $1.7 billion, marks a pivotal moment for both companies.

Initial Payment and Future Milestones: Novartis will commence with an initial payment of $7.00 per share, totaling $0.8 billion. Additionally, Regulus shareholders are set to receive a contingent value right (CVR) that promises an extra $7.00 per share, contingent upon the regulatory approval of farabursen, Regulus' lead product candidate.

Leadership's Vision: "This merger with Novartis represents a thrilling opportunity to advance farabursen to patients suffering from ADPKD, a condition with currently limited treatment options," expressed Jay Hagan, CEO of Regulus. "Novartis' global development and commercial prowess is instrumental in bringing this potential new medicine to those in need."

Closing Conditions: The acquisition is pending standard closing conditions and regulatory approvals, with an anticipated completion in the latter half of 2025.